Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆijªÁø     (Date : 2016-07-13 10:22:21)
Á¦¸ñ [³í¹®] [2015]Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value
³»¿ë


Pancreas. 2015 Apr;44(3):484-92. doi: 10.1097/MPA.0000000000000280.

Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.

Kwon MJ1Jeon JYPark HRNam ESCho SJShin HSKwon JHKim JSHan BKim DHChoi YL.

Author information

1From the Departments of *Pathology and †Surgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang; Departments of ‡Pathology and §Surgery, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul; ¡¬Department of Hematological Oncology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang; and ¶Laboratory of Cancer Genomics and Molecular Pathology, Samsung Biomedical Research Institute, Samsung Medical Center, #Department of Pathology, Samsung Medical Center, Sungkyunkwan University College of Medicine, and **Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.

Abstract

OBJECTIVES:

Low prevalence and prognostic relevance of KRAS mutations in Korean pancreatic ductal adenocarcinomas (PDACs) need to be validated with sensitive detection method.

METHODS:

Peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping was used to precisely detect KRAS mutation in 72 paraffinized tumor samples and was validated by pancreatic cell lines to compare the efficiency of direct sequencing.

RESULTS:

The PNA-mediated PCR clamping detected mutant allele proportions of as low as 0.5% against a background of wild-type DNA and was 20-fold more sensitive than direct sequencing through the validation of pancreatic cell lines. Peptide nucleic acid-mediated PCR clampingdetected KRAS mutations in 47.2% of 72 PDACs. Low tumor cellularity and low PCR amplification efficiency led to be undetected or failed by direct sequencing in pancreatic paraffinized samples.KRAS mutations were an independent worse prognostic factor predicting a reduced progression-free survival rate in the postoperative chemotherapy group.

CONCLUSIONS:

Peptide nucleic acid clamp real-time PCR was a sensitive method for detecting KRAS status in paraffinized PDAC samples. We identified a low KRAS mutation rate among the Korean PDAC patients using PNA clamp real-time PCR, potentially implicating epidemiological characteristics. The low KRAS mutation rate and its prognostic role may suggest the further survival benefit in Korean PDAC patients.


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆijªÁø 28873
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆijªÁø 65535
¢º           [³í¹®] [2015]Low frequency of KR.. ÆijªÁø 29211
   46           [³í¹®] [2015]Simultaneous genoty.. ÆijªÁø 6067
   45           [³í¹®] [2014]Simultaneous diagno.. ÆijªÁø 20974
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆijªÁø 8124
   43           [³í¹®] [2013]Detection of EGFR m.. ÆijªÁø 1175
   42           [³í¹®] [2013]Detection and compa.. ÆijªÁø 5816
   41           [³í¹®] [2013]Detection of BRAF V.. ÆijªÁø 6097
   40           [³í¹®] [2013]Comparison of Direc.. ÆijªÁø 25286
   39           [³í¹®] [Microarray]Peptide nucle.. ÆijªÁø 14321
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆijªÁø 22242
   37           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆijªÁø 3387
   36           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆijªÁø 14157
   35           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆijªÁø 1166
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆijªÁø 4027
   33           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆijªÁø 8822
   32           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆijªÁø 14477
   31           [³í¹®] [ÆijªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆijªÁø 1171
   30           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆijªÁø 3893
 

< 1 2 3 >